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What was known before: 1 
• There is some data on the occurrence and natural history of peripapillary choroidal 2 
neovascularisation (PPCNV) in hospital settings but a paucity of data exists on the epidemiology of 3 
PPCNV in community populations • There is no detailed description of the prevalence and features 4 
of asymptomatic PPCNV  5 
 6 
 7 
What this study adds: 8 
• This represents the first study to report PPCNV occurs with a population prevalence of 0.29%, 9 
and is bilateral in 0.06% in the UK Caucasian population >65 years. • Gender specific prevalence 10 
was 0.36% and 0.19% for females and males respectively. • PPCNV are commonly located nasal 11 
to the optic disc and are small and asymptomatic early on. • Peripapillary RPE degenerative 12 
changes, drusen and RPD, as well as higher grade ARM predispose to PPCNV.  13 
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Abstract 47 
Purpose: There is paucity of data on the epidemiology of peripapillary choroidal 48 
neovascularisartion (PPCNV). Our aim was to determine prevalence of PPCNV in the elderly 49 
UK population of Bridlington residents aged ≥ 65 years. 50 
Methods: Eyes with PPCNV in the Bridlington Eye Assessment Project (BEAP) database of 51 
3475 participants were analysed. PPCNV outline was drawn, its area measured, and clock-52 
hour involvement of disc circumference recorded. Location and shortest distance from the 53 
lesion edge to fovea were recorded. Masked grading for age-related maculopathy 54 
(ARM)/reticular pseudodrusen (RPD) within the ETDRS grid was assigned for each eye using 55 
a modified Rotterdam scale. Peripapillary retinal pigment epithelial (RPE) changes/drusen 56 
were recorded. Visual acuity (VA) and demographic details analysed separately were 57 
merged with grading data.  58 
Results: PPCNV were identified in 10 subjects, and were bilateral in 2 (20%), a population 59 
prevalence of 0.29%, and 0.06% bilaterality. Gender specific prevalence were 0.36%, 0.19% 60 
for females and males respectively. Age ranged from 66 to 85 years (mean 76.3 [SD 6.4]. 61 
PPCNV were located nasal to disc in 41.7%, measuring 0.46-7.93mm2 [mean 2.81mm2 (SD 62 
2.82)]. All PPCNV eyes had peripapillary RPE changes. One subject had no ARM, 1 angioid 63 
streaks, and 30% RPD. No direct foveal involvement, or reduced VA attributable to PPCNV 64 
was observed. 65 
Conclusion: PPCNV were infrequent in this population, more common in females, and often 66 
located nasal to the disc, without foveal extension. Peripapillary degenerative changes were 67 
universal, and strong association with ARM was observed in eyes with PPCNV. Typically, 68 
PPCNV were asymptomatic with VA preservation. 69 
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Introduction 70 
Peripapillary choroidal neovascular membranes (PPCNV) form part of the spectrum of 71 
diseases that have potential to cause severe visual loss.1 They are well-recognized but 72 
uncommon, reportedly accounting for less than 10% of all newly presenting choroidal 73 
neovascular membranes (CNV).2,3 In a survey by Browning and Fraser4, PPCNVs were 74 
associated with Age-Related Macular Degeneration (AMD) in 45% of cases, while 39% were 75 
considered idiopathic. PPCNV are also associated with conditions such as inflammatory 76 
diseases including presumed ocular histoplasmosis5, uveitis6-9, and chorioretinitis10, and 77 
degenerative processes including myopia11 and angioid streaks.4 Choroidal osteoma, optic 78 
disc drusen and congenital disc anomalies are other rare associations.  Our group has 79 
previously reported that PPCNV occurred in 9 out of 231 cases of newly presenting CNV in a 80 
UK hospital setting (3.9%).2 Previous reports on the prevalence and associations of PPCNV 81 
are based on case reports or small case series from hospital data. To the best of our 82 
knowledge, there are no reports on population prevalence of PPCNV except for our 83 
previous report of worse eye prevalence of 0.29% for Grade 4c (PPCNV), compared to 1.8% 84 
for neovascular AMD (nAMD) (grade 4b AMD) and 2.5% for geographic atrophy (GA) (grade 85 
4a AMD).12 Furthermore, there is no data available in the literature on the population 86 
prevalence of asymptomatic PPCNV. 87 
In this study, characteristics of eyes classified as having PPCNV from the Bridlington Eye 88 
Assessment Project (BEAP) were investigated.  89 
Methods 90 
The BEAP study methods, including image acquisition and analysis, have been reported 91 
previously.12 In summary, the BEAP is a single centre population based prevalence study, 92 
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with the primary objective to investigate the utility of screening for eye disease in an elderly 93 
population ≥ 65 years, using clinical examination by trained optometrists and digital imaging 94 
technology. All individuals registered with a General Practitioner in Bridlington and 65 years 95 
and older on the 5th November 2002 were eligible for inclusion in the project. Subjects 96 
known to be moving in or out of the area during the study, those that were registered blind 97 
or partially sighted, bed bound individuals or those known to have significant dementia 98 
were excluded from the study. Subjects were invited by letter on a street-by-street basis in 99 
ascending numerical order of postcode. When contacted, each subject was invited to 100 
telephone the BEAP to make an appointment to be examined. At its completion in March 101 
2006 over 3500 subjects had been examined. All participants were interviewed, in person, 102 
by a trained research nurse using structured questionnaire, and examined by one of four 103 
specially trained optometrists with structured proforma completed by the research staff. 104 
Non-stereoscopic mydriatic fundus photography was performed with a Topcon fundus 105 
camera (model TRC NW6S) and a Nikon 10-megapixel camera. Each eye had a 30° colour 106 
fundus photograph (CFP) taken centred on the macula. Local ethics committee approval 107 
(Ref No. PB/RH/02/288) was obtained and the research adhered to the tenets of the 108 
Declaration of Helsinki. All subjects provided informed consent. Masked image grading was 109 
performed in accordance with the International Classification System of AMD, using 30° 110 
non-mydriatic colour fundus photographs. All photographs of right and left eyes were 111 
graded by a single ophthalmologist (CW) who was trained in image grading at the Central 112 
Angiographic Reading Facility (CARF), Belfast, Northern Ireland. One in ten (1 in 10) 113 
randomly selected right eye images were sent to the CARF for secondary masked grading by 114 
certified graders.  115 
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The diagnosis of PPCNV was clinical, and based on surrogate clinical features of CNV (as 116 
previously described) 12 directly adjacent to and contiguous with the optic disc. These 117 
include definite RPE detachment, haemorrhagic or serous, and/or subretinal or sub-RPE 118 
haemorrhages unassociated with any other vascular lesion and/or intraretinal, subretinal or 119 
sub-RPE glial tissue, and/or subretinal or sub-RPE neovascular membrane as characterized 120 
by grey/yellowish discoloration. All eyes identified as having PPCNV, or questionable lesions 121 
were reviewed and scrutinised by a retinal specialist (WMA). Any differences in opinion 122 
were sent to CARF for secondary grading. All images were analysed using the Topcon 123 
IMAGEnet 2000 program. All eyes identified with PPCNV (and corresponding contralateral 124 
eyes) were subsequently reviewed in greater detail, with demographic details and visual 125 
acuity (VA) unknown to the grader. The outline of the PPCNV was drawn and area 126 
measured. Location of the lesion was also recorded. The PPCNV area was taken to include 127 
only visible membrane (as indicated by a grayish-brown or whitish-grey appearance) and/or 128 
areas of sub-retinal or sub-RPE haemorrhage. Areas of obvious peripapillary glial tissue, if 129 
associated with haemorrhage were also measured as part of the lesion. Often, the lesion 130 
would be located adjacent to the disc, with peripheral edge haemorrhage or exudate. Areas 131 
of subretinal fluid (SRF) without any haemorrhage were not in themselves measured as part 132 
of the lesion. Only areas of gross exudation immediately adjacent to haemorrhage or 133 
membrane were included in the measured area, whereas sparse distal exudates were not. 134 
The extent/severity of the PPCNV was recorded using clock hours of involvement of the 135 
optic disc circumference. An example of a PPCNV is shown in Figure 1. 136 
Signs of age related maculopathy (ARM) within an ETDRS macular grid were recorded using 137 
a modified Rotterdam grade as previously described.12 Retinal pigment epithelial (RPE) 138 
changes and presence of drusen in the peripapillary area (one-disc diameter around the 139 
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optic disc) were specifically recorded along with the closest distance from the edge of 140 
changes secondary to the PPCNV, including SRF to the fovea. ARM changes in the 141 
contralateral eyes were recorded.  142 
VA and demographic details which were analysed separately were then merged with the 143 
image grading data. 144 
Statistical analysis was performed using Stata 12.0 (StataCorp, College Station, TX) and SPSS 145 
v.22 (IBM Corp. Armonk, NY). Patient demographic characteristics that are categorical will 146 
be summarised using percentages and continuous normally distributed variables with the 147 
presentation of means, standard deviation and associated 95% confidence intervals. 148 
Where the continuous variable is non-normally distributed we will present medians and 149 
associated quartiles (25th, 75th). Statistical significance will be shown when P-values <0.05. 150 
Results 151 
Amongst the total of 3475 participants with gradable photographs in at least one eye, 152 
PPCNV were identified in 10 subjects (Table 1), with bilateral occurrence in 2 individuals 153 
(20%). This resulted in a total of 12 eyes with PPCNV, and an overall population prevalence 154 
of 0.29%. PPCNV accounted for 12 (13.3%) of a total of 90 cases of CNVMs identified in the 155 
BEAP Study. Seven individuals (70%) were female resulting in gender specific prevalence 156 
rates of 0.36% (7/1939) and 0.19% (3/1536) for females and males respectively. Bilateral 157 
involvement equated to a population prevalence of 0.06%. Ages ranged from 66 to 85 years, 158 
with a mean of 76.3 years (SD 6.4). There was no obvious increase in prevalence with age, as 159 
shown in Table 2 (p=0.77).   160 
Eyes with PPCNV had a higher prevalence of the more advanced stages of AMD when 161 
compared to the overall BEAP cohort. The prevalence of Rotterdam grade 2, 3 or 4a within 162 
the macula in PPCNV eyes was considerably high at 42% compared to that in the general 163 
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population (see Tables 3 and 4). Only 1 eye in the ten individuals with a PPCNV had 164 
minimal/no sign of ARM present (Rotterdam grade 0). 165 
One subject (10%) had identifiable angioid streaks. This individual was removed from our 166 
initial report of AMD prevalence 12 as the pathology was not felt to be purely age-related. 167 
The patient was 81 years of age and had co-morbid large soft drusen within the macula. No 168 
individuals with PPCNV had pathological myopia or optic disc pathology, such as disc drusen 169 
or disc swelling, or evidence of previous chorioretinitis. None of the eyes with PPCNV had 170 
direct involvement of their fovea with SRF, exudate or haemorrhage in the photographs. 171 
Visual function was good in all eyes, with none having poor VA secondary to PPCNV. Eyes 172 
with reduced vision had co-morbid conditions as summarized in Table 3. Patient Number 10 173 
(LogMAR VA 0.22, Snellen VA=20/32) had a co-morbid epiretinal membrane. Patient 2 174 
(LogMAR VA of 0.42 [Snellen 20/50]), subsequently underwent cataract surgery and 175 
postoperatively had a VA of 0.2 [Snellen 20/30]. Subject 4 had a LogMAR VA of 0.3 [Snellen 176 
20/40] at presentation. This eye had a 23-months follow-up in a hospital eye service, after 177 
which the patient was reported to have a haemorrhagic peripapillary scar with atrophy and 178 
discharged from further follow-up. The VA reduction was attributed in part to secondary 179 
macula RPE atrophic changes.  180 
Table 3 details demographic and macular changes in participants with PPCVN. Table 4 181 
summarises the peripapillary retinal changes, along with size (area) and locations of CNV in 182 
relation to the optic disc in all eyes with PPCNV. Three eyes of 3 subjects (30%) with PPCNV 183 
had reticular pseudodrusen (RPD). Nine (9) out of 10 individuals (90%) had evidence of 184 
drusen ≥63µm in size within the macular area, including the one with angioid streaks. One 185 
individual (10%) had contralateral nAMD; another had bilateral GA with multiple large 186 
drusenoid pigment epithelial detachments that appeared completely separate from any 187 
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PPCNV (which was nasal to the disc). All eyes with PPCNV had RPE hyperpigmentary, 188 
hypopigmentary or atrophic changes around the optic disc. One eye (8.33%) had a large 189 
PPCNV involving ≥6 clock hours. Six (6) of the 12 identified PPCNM had predominantly 190 
temporal location with another occurring superiorly. Five of 12 PPCNVs (41.7%) involved 191 
retina nasal to the optic disc only. The PPCNV size ranged from 0.46 mm2 to 7.93 mm2 with a 192 
mean of 2.81 mm2 (SD 2.82, 95% CI 1.1 - 4.6). The mean area of PPCNV in the 4 eyes with 193 
visible exudation was 5.64 mm2 (95% CI 0.57 - 10.72). For the 8 eyes with no visible 194 
exudation, the membranes measured an average of 1.39 mm2 (95% CI 0.47 - 2.31). 195 
Discussion 196 
This study reports the prevalence of PPCNV within an elderly Caucasian population, using 197 
data from the largest UK population based screening study of AMD to date. To the best of 198 
our knowledge, this represents the first population study specifically to report on the 199 
prevalence of PPCNV, as well as describe the characteristics of PPCNV and concomitant 200 
ocular findings in affected and fellow eyes, as all previous publications on the subject were 201 
based on hospital cohorts, in predominantly symptomatic individuals, with inherent 202 
selection bias. Our results indicate that as many as two thirds of PPCNV may remain 203 
asymptomatic, compatible with the finding that 40% of the lesions are located nasal to the 204 
disc. 205 
PPCNVs (grade 4c AMD) were an infrequent finding, considerably lower than the prevalence 206 
of grade 4b AMD, in the same population.12 Our findings are similar to those of some 207 
previous published studies13, 14, where there was a female preponderance. RPD are known 208 
to have such female predilection.12,16 However, it is unlikely that the increased female 209 
prevalence of PPCNV in this study is due   to the presence of RPD, as the three patients with 210 
RPD and PPCNV in the series were male. We have previously reported that PPCNV 211 
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accounted for 3.9% of newly diagnosed cases of CNV in AMD in a hospital eye service.2 212 
Other investigators have reported frequency of <10% of all CNVs.15 This relatively low 213 
prevalence is confirmed in this study, where PPCNV accounted for 13.3% of all identified 214 
CNVs.  215 
The majority of PPCNVs in this cross-sectional study were unilateral, similar to what was 216 
reported at baseline in hospital based longitudinal studies. 4, 14 In the Silvestri study14, only 2 217 
out of the 14 (14%) individuals had bilateral PPCNV at their initial presentation, whilst 218 
others developed contralateral eye involvement over follow up of up to 7 years resulting in 219 
54% bilteralism.14 Similarly, Browning et al reported bilateral involvement in 19 of their 96 220 
patients (19.8%)4 after a median follow up of 2 years.  221 
There is a myriad of reported associations between PPCNV and other conditions, most of 222 
which are based on single case reports or small case series. Larger hospital based studies 223 
also exist, but may give a poor representation of the true spectrum of disease as small, 224 
nasal, age-related PPCNVs may remain asymptomatic. In a series of 115 eyes of 96 patients, 225 
Browning et al reported ocular conditions associated with PPCNV as 45.2% ARM, 39.1% 226 
idiopathic, 4.3% multifocal choroiditis, 2.6% angioid streaks, 1.7% presumed ocular 227 
histoplasmosis, 1.7% choroidal osteoma, 0.9% optic disc drusen and 0.9% congenital disc 228 
anomalies.4 The definition of ARM was however broad, and included all eyes with ≥1 of 229 
drusen >63µm, pigment clumps, mottled pigment epithelial atrophy, GA and signs of an 230 
exudative AMD, including disciform scars in both eyes.4 They also reported that 39% of 231 
subjects with PPCNV had drusen on colour photography.4 Kies and Bird similarly reported 15 232 
of their 55 eyes (27%) with PPCNV had identifiable drusen13, and Silvestri et al reported that 233 
60% of PPCNV were related to age-related degenerative changes.14 In the present series, 234 
the presence of drusen ≥63um within the macular area in 90% of cases was much higher 235 
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than previously published.  This higher prevalence of PPCNV in eyes with the more 236 
advanced stages of AMD when compared to the overall BEAP cohort could be a chance 237 
finding, but suggests a stronger association of PPCNV with ARM than previously published. 238 
The lower prevalence of ARM reported within hospital populations could, in part, be 239 
explained by the fact that these are symptomatic, and more likely to be large lesions with 240 
macula involvement from exudation or SRF which could mask drusen or result in their 241 
regression. Alternatively, it could reflect the older age of the cohort included in the present 242 
study. RPD or subretinal drusenoid deposits (SDD) cover a large area of the retina including 243 
the peripapillary zone16,17, and are known to be associated with nAMD.18-20 We have 244 
previously reported their prevalence in 22% of eyes with newly presenting nAMD in a 245 
hospital eye service19, a finding similar to that in participants with PPCNV in this population.  246 
Peripapillary degenerative changes in the present series were a more universal finding when 247 
compared to the presence of macular drusen. Previous studies on PPCNV have not reported 248 
the presence of drusen or pigmentary change in the immediate peripapillary area. Recent 249 
studies have reported the presence of peripapillary SDD in association with drusen and 250 
other age related changes using multimodal imaging.16,17 As drusen and pigmentary changes 251 
within the macula are known hallmarks of both GA and CNV, and SDD predispose to CNV, it 252 
seems logical to consider these changes in the peripapillary area as potentially pathological 253 
for PPCNV. Older reports have speculated on potential relationship of previous unwitnessed 254 
episodes of multiple white dot syndromes in the aetiology of the relatively large cohort of 255 
presumed idiopathic PPCNVs.21, 22 A more plausible explanation would be that localized, 256 
age-related changes occurring in the peripapillary area may predispose to localized breaks in 257 
Bruch’s membrane allowing CNV membranes to develop as reported by Sarks.23   258 
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The association with angioid streaks and PPCNV is well established.24-27 The number of such 259 
cases is small, but suggests that membranes occurring in the region of angioid streaks 260 
remain small and asymptomatic and, therefore, are less likely to present to a hospital eye 261 
service. Potential overlaps between the aetiologies of PPCNV in patients with angioid 262 
streaks and comorbid age-related changes are possible.  263 
Some authors have defined a PPCNV as large if it covered more than 3.5 disc areas or 264 
involved over 50% of the disc circumference.28 Only one subject (10%) in the current series 265 
had >6 clock hours involved. This figure is similar to the 15% prevalence of large membranes 266 
reported by Browning et al4, but less than the higher prevalence of 87% of large membranes 267 
involving more than 6 clock hours reported by Kies and Bird.13 There was complete disc 268 
encirclement by the PPCNV in 0.9% of Browning’s cases4 whilst 11% in Kies and Bird series13 269 
had similar features4, probably reflecting selection bias. Caution should however be 270 
exercised when comparing the size of CNV lesions, given the different imaging modalities 271 
used in the different studies, especially as PPCNV may be larger in surgical excision and 272 
indocyanine green angiography than on FFA.13, 28-30  273 
The finding of asymptomatic PPCNVs in this study is interesting.   Our literature search could 274 
not find any studies on the prevalence of asymptomatic PPCNV. Sarks provides the best 275 
insight on the subject, with a clinicopathological correlative study of 150 eyes of 80 patients 276 
obtained post-mortem23, which identified CNVMs in the peripapillary area in 14%, macular 277 
area in 20%, and in the peripheral retina in 24.6% of eyes. Unlike the large temporal PPCNVs 278 
seen in eyes of symptomatic individuals which had extended to the fovea14, 23, 31, Sarks 279 
suggested that in older subjects, small and frequently nasal asymptomatic PPCNV occurred 280 
with greater frequency than large, temporal membranes with macula involvement, and 281 
demonstrated that PPCNVs originate from choroidal vessels passing either through breaks in 282 
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Bruch’s membrane (57%) or from vessels extending around the termination of Bruch’s 283 
membrane (43%) especially on the nasal side.23  284 
Limitations of our study include utilization only of CFP of field 2. Although the disc and nasal 285 
peripapillary areas were well included in these images, the addition of CFP of field 1, 286 
centered on the optic disc may have added clearer delineation of nasal PPCNV.  Multimodal 287 
imaging including SD-OCT around the optic disc, combined with angiography in suspected 288 
cases would also have improved case detection, and are recommended in future population 289 
studies. Individuals registered as blind or partially sighted were excluded from study 290 
inclusion. However, our analysis showed that such subjects were few, and had subfoveal 291 
CNV. We cannot be sure that some of these individuals may have had poor vision secondary 292 
to PPCNV which could be bilateral or in combination with other visually significant ocular 293 
pathology. Such scenarios would make our prevalence measure an underestimation.   294 
In conclusion, this study confirms that PPCNV are an infrequent finding in the elderly 295 
population compared to macular CNV, and have a clear female preponderance. PPCNV may 296 
be asymptomatic especially when small or located nasally. This finding is very distinct from 297 
that in previous hospital studies of symptomatic patients, and supports the early 298 
histopathological study23 which suggested that in elderly individuals, PPCNV frequently 299 
occurred in a nasal position and are asymptomatic in the majority of cases.  This study also 300 
reports the universal finding of peripapillary degenerative changes in all eyes with PPCNV, 301 
and a strong association between PPCNV and signs of ARM within both the macula and 302 
immediate peripapillary areas plus association with RPD.  Multimodal imaging such as OCT, 303 
FFA and ICG would help identify possible phenotypic variants.  More research is also 304 
required on the natural history of these lesions, including those that are located nasally. 305 
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Summary 398 
What was known before 399 
• There is some data on the occurrence and natural history of peripapillary choroidal 400 
neovascularisation (PPCNV) in hospital settings but a paucity of data exists on the 401 
epidemiology of PPCNV in community populations 402 
• There is no detailed description of the prevalence and features of asymptomatic 403 
PPCNV 404 
 405 
What this study adds 406 
• This represents the first study to report PPCNV occurs with a population prevalence 407 
of 0.29%, and is bilateral in 0.06% in the UK Caucasian population >65 years.  408 
• Gender specific prevalence was 0.36% and 0.19% for females and males respectively.  409 
• PPCNV are commonly located nasal to the optic disc and are small and asymptomatic 410 
early on. 411 
• Peripapillary RPE degenerative changes, drusen and RPD, as well as higher grade 412 
ARM predispose to PPCNV. 413 
 414 
 415 
 416 
 417 
 418 
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Figure Legends 443 
Figure 1. Non-stereoscopic colour fundus photograph. A peripapillary choroidal neovascular 444 
membrane involving the temporal 6 clock hours of the optic disc circumference is present, and 445 
associated with exudation. There are visible co-morbid reticular pseudodrusen present in the macula 446 
and elsewhere. 447 
 448 
 449 

Table 1: Population based prevalence of PPCNV in the Bridlington Eye Assessment Project 
(BEAP). Data is number (%) [95%CI]. 
 
 
Grade Right Eye 
(3340 gradable 
photos) 
Left Eye 
(3384 
gradable 
photos) 
Participants 
(3475 
gradable 
photos) 
Bilateral 
(3255 
participants 
with gradable 
photos in 
both)  
PPCNV/4c 6 (0.18) 
[0.07-0.40]  
6 (0.18) 
[0.07-0.40]  
10 (0.29) 
[0.15-0.54]  
2 (0.06) 
[0.01-0.24] 
Mean Age 
(years)  
 
76.7 
 
73.6 76.3 69.5 
 
 
 
Table 2: Age (years) specific prevalence of PPCNV. Data is number (%) [95% CI]  
 
Age range 
(years) 
65-69 70-74 75-79 80-84 85-89 >90 Total 
Number of 
PPCNV eyes 
(%)  
[95% CI]  
 
2 (0.24) 
[0.01- 
0.91]  
 
1 (0.09) 
[0.01-
0.58]  
 
3 (0.37) 
[0.07- 
1.14]  
 
3 (0.56) 
[0.11- 
1.72]  
 
1 (0.55) 
[0.01- 
3.34]  
 
0 (0.00) 
[0.00- 
12.39]  
 
10 (0.29) 
[0.15-
0.54]  
 
Total gradable 
eyes available 
849 1069 808 533 183 33 3475 
 
Table 3: Summary of demographic details of eyes with PPCNV and associated macular age-related changes (Rotterdam Grades), with 
LogMAR visual acuity (VA) 
Number Affected eye Age at exam Sex (Macular Status) 
AMD Grade Right 
(Macular Status) 
AMD Grade Left 
Right VA 
(LogMAR) 
Left VA 
(LogMAR) 
Cause of Vision loss 
1 LE 66 F 1a 1a 0.02 0.14 nil 
2 LE 76 F 1a 1a 0.30 0.42 Other: cataracts 
3 LE 76 F 1a 1a 0.1 0.1 nil 
4 LE 85 M 4b 4, reticular drusen CF 0.3 ARM 
5 RE 83 F 0a 0b 0.2 0.2 nil 
6 BE 72 F 1a 1a 0.1 0.1 nil 
7 RE 77 M 2a, reticular drusen 2a, reticular drusen 0.2 0.2 nil 
8 RE 80 M 3, reticular drusen 3, reticular drusen 0.0 0.0 Nil 
9 BE 67 F 4a 4a 0.3 0.4 RE AMD-GA, LE diabetic CSMO 
10 (angioid 
streaks) 
RE 81 F 1a Cannot grade 
(Non-AMD) 
0.22 0.36 RE-ERM, LE-cataract 
1 
 
Table 4: Summary of the peripapillary retinal changes along with size (area) and locations of CNV in relation to the optic disc in all the eyes 
with PPCNV. 
 
Number Affected eye Features of the peripapillary 
disc area ipsilateral eye 
Features of the peripapillary disc area 
contralateral eye 
Maximum 
drusen 
diameter 
(µm) 
ipsilateral 
eye 
Maximum 
drusen diameter 
(µm) 
contralateral eye 
Signs of PPCNVM Area of 
PPCNVM 
(mm2) 
Distance 
from 
edge of 
lesion to 
fovea 
(mm) 
Clock hours 
(S=Superior, 
I=inferior, N=Nasal, 
T=Temporal) 
1 LE RPE atrophy RPE hyperpigmentary crescent and some RPE 
atrophy 
90 210 RPE changes and subretinal 
haemorrhage, visible membrane 
3.90 2.89 3 (11-2 S) 
2 LE Alpha zone changes with 
hypopigmentation and 
drusen visible 
A pigmented crescent of RPE hyperpigmentation 
temporally with more widespread 
hypopigmentation 
250 130 Peripapillary haemorrhage and 
RPE changes 
1.39 5.68 2.5 (6.30-9 IN) 
3 LE Hypopigmentation around 
disc with drusen 
Focal area of RPE atrophy with scleral show. 
RPE hyperpigmentation  
250 160 Multiple peripapillary subretinal 
haemorrhages and exudate 
6.49 2.18 5 (12.30-5.30 T) 
4 LE There is a rim of RPE 
atrophy around the disc with 
extensive atrophy beyond 
Extensive atrophy 150 0 (4b) Haemorrhage surrounded by 
disciform scar and atrophy 
1.23 2.21 1.5 (2.30-4 T) 
5 RE There is a RPE 
hyperpigmentary crescent 
and areas of 
hypopigmentation and 
atrophy 
Small area of RPE atrophy with more widespread 
hyperpigmentation/hypopigmentation 
0 ≤63 Subretinal haemorrhage 1.42 4.87 2 (4-6 IN)  
6 BE RPE atrophy with 
hyperpigmentary crescent 
RPE atrophy LE withy hyperpigmentation and 
hypopigmentation 
200 RE 
220 LE 
NA RE-multiple haems and atrophy 
LE-Haemorrhages and atrophy 
0.58 RE 
0.46 LE 
3.20 RE 
3.34 LE 
RE: 1.5 (7.5-9 IT) 
LE: 1.5 (3-4.30 ST) 
2 
 
 RE 
7 RE RPE atrophy with more 
widespread 
hypopigmentation 
RPE atrophy with more widespread 
hypopigmentation 
190 210 Subretinal haemorrhage 0.63 5.07 2 (12-2 SN) 
8 RE RPE atrophy and reticular 
drusen 
RPE atrophy and reticular drusen 170 190 Gross exudation, visible membrane, 
retinal thickening 
7.93 1.52 6 (12-6 T) 
9 BE RPE atrophy and 
hyperpigmentation with 
drusen RE 
RPE atrophy and hyperpigmentation and 
hypopigmentation 
450 230 RE: Gross exudation, haemorrhage 
and retinal thickening 
LE: subretinal haemorrhage and 
pigmentary changes 
RE: 7.21 
LE: 1.49 
RE: 6.29 
LE: 3.19 
RE: 5 (12-5 N) 
LE: 1 (1-2 ST) 
10 RE Angioid streaks with RPE 
atrophy and 
hyperpigmentation 
Angioid streaks 265 Cannot grade as 
poor quality 
photo, but 
questionable 
PPCNVM with 
haemorrhage 
Haemorrhage with exudate 0.94 5.59 1 (4.5-5.5 IN) 
